* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Lec. 4 - Atypical In..
Anaerobic infection wikipedia , lookup
Hepatitis B wikipedia , lookup
Marburg virus disease wikipedia , lookup
Dirofilaria immitis wikipedia , lookup
Sexually transmitted infection wikipedia , lookup
Schistosomiasis wikipedia , lookup
Oesophagostomum wikipedia , lookup
Coccidioidomycosis wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Neonatal infection wikipedia , lookup
Tuberculosis wikipedia , lookup
Mycoplasma pneumoniae wikipedia , lookup
Atypical Infections: Mycoplasma, Mycobacterium, Chlamydia Chijioke Onejeme [email protected] 1 Objectives To identify Mycoplasma virulence factors To identify the infectious diseases caused by Mycoplasma species To identify the unique biological and biochemical properties of Mycoplasma species Discuss the biological, physiological and biochemical characteristics of chlamydial agent. Discuss the major chlamydial human pathogens from the standpoint of: A. B. C. D. E. Human diseases produced Clinical features of disease Mechanism of pathogenesis of spirochetal pathogen inducing disease. Clinical diagnosis of disease. Treatment and prevention of disease induced by those agents. 2 Mycoplasma Lack peptidoglycan Pleomorphic (takes on many different shapes) Cell membranes contains sterols Facultative anaerobe Smallest genome (minimal amount of nucleic acid to form cell) 3 Mycoplasma 4 Mycoplasma pneumoniae Primary atypical pneumonia (typical due to strep) Transmission via coughing or sneezing Incubation up to 3 weeks before symptoms Symptoms Fever, headache, non-productive cough (strep produce a lot of material) Treatment (macrolides) Erythromycin, Tetracycline ; Penicillin is ineffective Mechanism of Pathogenicity Virulence Factor – P1 adhesion Binding of M. pneumoniae to respiratory cells via P1 protein. Damage of respiratory cells 5 6 Other Mycoplasma Ureaplasma urealyticum Implicated in non gonococcal urethritis (NSU) Mycoplasma hominis Implicated in pelvic inflammatory disease 7 Endotoxin Present in the outer membrane Released in the extracellular space Mediates the release of cytokines (it alone) TNF, Il-1, Il-6 Activation of disseminated intra vascular coagulation (DIC) (release of clotting factors) Vascular damage, increased vascular leakage Septic shock 8 9 10 M. tuberculosis General Features They are obligate aerobes and grows very slowly with a generation time of 12-15 hours. On solid media the colonies are raised and rough with a wrinkled surface. M. tuberculosis cells grow either as discrete rods or as aggregates. Virulent strains tend to grow as an aggregated long arrangement called serpentine cord. Cord factor is a derivative of mycolic acids, trehalose 6'-dimycolate. 11 - Unique structures: arabinogalactan (AG), mycosides, sulfatide, and lipoarabinomannan (LAM). - Unique component of lipids is mycolic acid. - Waxes, account for 60% of cell weight, are composed of lipids and some polypeptides. - It can be visualized by acidfastness stains. 12 13 Acid Fastness Stain (Ziehl-Neelsen stain) flood the slide with basic fuchsin (a red dye) in 5% phenol as a mordant. heat gently for few minutes to melt the wax. (so red dye can penetrate outer cell - mycolic) wash with 3% HCl in ethanol. (wash out colors except those inside cell) counter-stain with methylene blue. 14 15 Host Immune Response (Review) Humoral immune response antibodies, cytokines (TNF, IL) Cell-mediated immune response T cells, macrophages 16 Phagocytosis of Invading Microbes 1. Oxygen radicals 2. Lysosomal hydrolytic enzymes 17 Survival of M. tuberculosis in Macrophages Reduction of reactive oxygen radicals production. Resistance to oxidative killing. AG and LAM absorb oxygen radicals. No phagosome and lysosme fusion. M. tuberculosis survives and multiplies inside the macrophages. Modify the surface structure of phagosome with AG and LAM. Keep the phagosome pH at neutral. Prevent the fusion of phagosome and lysomes, therefore no lysosomal enzymes digestion. 18 Multinucleated giant cells tubercles, granulomas Cell mediated immune response 19 Symptoms: Activation of macrophages -> cytokine secretion, IL-1: fever, TNF: lipid metabolism, weight loss, tissue necrosis (mucus production; deep cough; bloody sputum). Oxygen radicals: tissue damages Tissue necrosis -> inflammation -> mucous secretion, destruction of blood vessels -> frequent cough and bloody sputum 20 Primary TB Tuberculin test Miliary TB Ghon complex (latent) Reactivated TB 21 Tuberculin Skin Test Tuberculin is a mixture known as purified protein derivatives (PPD) from TB bacilli. It is a test for delayed type hypersensitivity (cell mediated immune response). Positive reaction, reddening and thickening (> 5mm) at the site of injection after 2-3 days, indicates cellular immunity to tubercle bacilli. 22 acetyl-CoA Oxaloacetate Fatty acid Citrate acetyl-CoA malate cis-aconitate MS glyoxylate ICL fumarate isocitrate succinate a-ketoglutarate ICL: isocitrate lyase MS: malate synthase 23 Factors for TB Crisis 1. An increased population of AIDS patients. HIV-infected persons are more susceptible to the TB bacilli and develop miliary TB. HIV infection can reactivate latent TB. AIDS patients could be tuberculin test negative. It relies on the cultivation of organism. Nosocomial transmission of TB is becoming serious. 2. An increased population of the homeless and in the prisons. 3. Increased immigration from countries where TB is common. 4. Occurrence of multi-drug resistant strains of M. tuberculosis. 24 Laboratory Diagnosis for M. tuberculosis A rapid diagnostic approach includes - a careful patient history, - tuberculin test, - chest X-ray, (for Ghon complex) - direct microscopic examination of sputum, - PCR reaction, (fast) - cultivation of microorganism. (takes long time) Time consuming for cultivation and antibiotic susceptibility assay. 25 Treatment and Prevention for Tuberculosis Drug Treatment Vaccination BCG is an attenuated M. bovis used as a mycobacterial vaccine. BCG is an abbreviation of bacillus Calmette- Guerrin, after its French discoverers. 26 Drug Treatment for Tuberculosis treated with a combination of multiple drugs for a long period of time: rifampin, isoniazid (INH), pyrazinamide, ethambutol, and streptomycin. Standard 9 month regimens a. INH (300mg) + RMP (600mg) + PZA (30 mg/kg) + STM (1 g) or EMB (25 mg/kg), orally, daily, for 2 months, INH (300mg) + RMP (600mg), orally, daily for 7 months. b. INH (300 mg) + RMP (600mg), orally, daily for 2 months, INH (900 mg) + RMP (600 mg), twice weekly for 7 months. Six month regimens INH-RMP-STM-PZA for 2 months + INH-RMP for 4 months 27 Antimycobacterium agents Rifampin - inhibits DNA-dependent RNA polymerase, kills intracellular and extracellular M.tb. Streptomycin - aminoglycoside, inhibits protein synthesis kills extracellular M.tb. Isoniazid (INH) - antimetabolite, inhibits mycolic acid synthesis, requires katG (catalase) for activity, kills intracellular and extracellular M.tb. Ethambutol - antimetabolite, inhibits RNA synthesis, kills intracellular and extracellular Pyrazinamide - disrupts membrane transport and energetics, kills intracellular M.tb. 28 M. leprae Infection It is exclusively a human parasite. It primarily proliferates inside macrophages. M. leprae has a predilection for skin and peripheral nerve. 29 Leprosy Leprosy is distinguished by its chronic slow progress and by its mutilating and disfiguring lesions. 1. Tuberculoid leprosy. - It is usually benign and frequently self-limited. Only segments of peripheral nerves are involved, leading to localized patches of anesthesia. - It is lepromin test positive. 2. Lepromatous leprosy - It is a malignant form of disease: formation of large firm nodules on the skin, loss of sensation in fingers and toes. - It is lepromin test negative. 3. Borderline leprosy. 30 Tuberculoid leprosy 31 Lepromatous leprosy 32 33 Leprosy Treatment and Prevention Drugs used: dapsone, rifampin, and clofazimine. No vaccine. 34 Previously, the family consisted of one genus, Chlamydia, with four species. Now the family has been divided into two genera, Chlamydia and Chlamydophila. The family Chlamydiaceae was revised extensively on the basis of genomic studies of these organisms 35 Differentiation of Chlamydiaceae That Cause Human Disease Chlamydia trachomatis Chlamydophila pneumoniae - - 36 Chlamydophila psittaci The Chlamydiaceae were once considered viruses because they are • Small enough to pass through 0.45-μm filters • Obligate intracellular parasites. The organisms have the following properties of bacteria: (1) possess inner and outer membranes similar to those of gram-negative bacteria; (2) contain both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA); (3) possess prokaryotic ribosomes; (4) synthesize their own proteins, nucleic acids, and lipids; and (5) are susceptible to numerous antibacterial antibiotics. 37 Unlike other bacteria, the Chlamydiaceae have a unique developmental cycle, forming metabolically inactive infectious forms (elementary bodies [EBs]) and metabolically active, noninfectious forms (reticulate bodies [RBs]). Microvilli cytoplasmic phagosomes fusion of cellular lysosomes with the EB-containing phagosome and subsequent intracellular killing is inhibited. 38 PHYSIOLOGY AND STRUCTURE EBs • Are resistant to many harsh environmental factors, non replicative infectious form. • Lack the rigid peptidoglycan layer found in most other bacteria. • Their outer membrane proteins are extensively cross-linked by disulfide bonds between cysteine residues. RBs • Are the metabolically active, replicating chlamydial form. • The extensive cross-linked proteins are absent in RBs, this form is osmotically fragile; • However, RBs are protected by their intracellular location. Other important structural components of Chlamydiaceae are a genus-specific lipopolysaccharide (LPS) Specific LPS Can be detected by complement fixation (CF) test and species specific outer membrane proteins. 39 COMPLEMENT FIXATION TEST 40 Chlamydia trachomatis Subdivided into three biovars, 1.Trachoma. 2.LGV (lymphogranuloma venereum): sexually transmitted disease caused by the invasive serovars L1, L2, L2a, or L3 3.mouse pneumonitis. Table 47-2. Clinical Spectrum of Chlamydia trachomatis Infections. antigenic differences in the major outer membrane protein (MOMP) Serovars Site of Infection A, B, Ba, C Primarily conjunctiva D-K Primarily urogenital tract L1, L2, L2a, L3 inguinal lymph nodes Biovar is a variant prokaryotic strain that differs physiologically and/or biochemically from other strains in a particular species. Serovars are those strains that have antigenic properties that differ from other strains. 41 PATHOGENESIS AND IMMUNITY Receptors for EBs are primarily restricted to non ciliated columnar, cuboidal, and transitional epithelial cells, which are found on the mucous membranes of the urethra, endocervix, endometrium, fallopian tubes, anorectum, respiratory tract, and conjunctiva. The LGV biovar replicates in mononuclear phagocytes present in the lymphatic system. The clinical manifestations of chlamydial infections are caused by (1)the direct destruction of cells during replication and (2)the host inflammatory response. 42 Cont, In LGV, the lesions form in the lymph nodes. Granuloma formation is characteristic. The lesions may become necrotic, attract polymorphonuclear leukocytes, and cause the inflammatory process to spread to surrounding tissues. Subsequent rupture of the lymph node leads to formation of abscesses or sinus tracts. Non-LGV serovars of C. trachomatis stimulates a severe inflammatory response consisting of neutrophils, lymphocytes, and plasma cells. 43 Cont, Infection does not confer long-lasting immunity. Rather, reinfection characteristically induces a vigorous inflammatory response with subsequent tissue damage. This response produces the vision loss in patients with chronic ocular infections, and scarring with sterility and sexual dysfunction in patients with genital infections. 44 CLINICAL DISEASES 1. Trachoma: caused by serovars A, B, Ba, and C. Initially, patients have a follicular conjunctivitis with diffuse inflammation that involves the entire conjunctiva. The conjunctivae become scarred as the disease progresses, causing the patient's eyelids to turn inward. The turned-in eyelashes abrade the cornea, eventually resulting in corneal Scarring , and loss of vision. 45 2. Adult Inclusion Conjunctivitis: • An acute follicular conjunctivitis • Caused by the C. trachomatis strains associated with genital infections (serovars A, B, Ba, D to K) • In sexually active adults. • The infection is characterized by -Mucopurulent discharge -Keratitis -Corneal scarring has been observed in patients with chronic infection. 3. Neonatal Conjunctivitis: Eye infections can also develop in infants exposed to C. trachomatis at birth. 4. Urogenital Infections : genital infections in men are symptomatic. The clinical manifestations include, cervicitis, endometritis, perihepatitis, salpingitis, and urethritis. 46 5. Reiter's syndrome (urethritis, conjunctivitis, polyarthritis, and mucocutaneous lesions) is believed to be initiated by genital infection with C. trachomatis 6. Lymphogranuloma Venereum : • Incubation of 1 to 4 weeks. • Stage1: A primary lesion appears at the site of infection. Painless. • Stage2: inflammation and swelling of the lymph nodes draining the site of initial infection. •Stage3: Systemic manifestations include fever, chills, anorexia, headache, and arthralgia. Mucopurulent cervicitis caused by Chlamydia trachomatis. 47 LABORATORY DIAGNOSIS (1) on the basis of cytologic, serologic, or culture findings. Examination of Giemsa-stained cell scrapings for the presence of inclusions. Not sensitive. Culture is the most specific method of diagnosing C. trachomatis infections The bacteria infect a restricted range of cell lines in vitro e.g., HeLa McCoy HEp-2 Derived from human cervical cancer cells. Derived from the synovial fluid in the knee joint of a patient . Derived from rat tumors. 48 Chlamydia trachomatis is grown in cell cultures and detected by staining inclusion bodies (arrows) with either iodine or specific fluorescein-labeled antibodies. 49 (2) Direct detection of antigen in clinical specimens. a. Immunofluorescence staining with fluorescein-conjugated monoclonal antibodies. b. ELISA: Enzyme Linked Immunosorbent Assay IN BOTH TECHNIQUES: antibodies are used that have been prepared against either the chlamydial MOMP or the cell wall LPS (3) Molecular probes. Specific but insensitive for the detection of small numbers of chlamydiae. 50 TREATMENT, PREVENTION, AND CONTROL Penicillin is ineffective against Chlamydia because they lack peptidoglycan in their cell wall. LGV: treated with a tetracycline (e.g., doxycycline) for 21 days. Children younger than 9 years, pregnant women, and patients unable to tolerate tetracyclines. macrolide (e.g., erythromycin, azithromycin) or sulfisoxazole is recommended. It is difficult to prevent C. trachomatis infections because the population with endemic disease commonly has limited access to medical care. The blindness associated with advanced stages of trachoma can be prevented only by prompt treatment of early disease and the prevention of reexposure. Improving sanitary conditions. Chlamydia conjunctivitis and genital infections are prevented through the use of safe sex practices and the prompt treatment of symptomatic patients and their sexual partners. 51 Special Thanks to Paula for compiling the slides 52